Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ (2002) Proc Natl Acad Sci U S A 99: 2830-5 Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Ao M, Williams K, Bhowmick NA, Hayward SW (2006) Cancer Res 66: 8007-16 Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT (1995) Cancer Res 55: 1215-20 Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM, Spencer DM (2003) Cancer Res 63: 8256-63 Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR (2000) Cancer Res 60: 6008-17 Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ (1986) Cancer Res 46: 1535-8 Cytokine genetic polymorphisms and prostate cancer aggressiveness. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC (2009) Carcinogenesis 30: 1358-62 Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS, Ukoli FM, Blot WJ (2006) Cancer 107: 2361-7 A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH. Klotsman M, Weinberg CR, Davis K, Binnie CG, Hartmann KE (2004) Pharmacogenomics J 4: 251-9 Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ (2016) Endocrinology 157: 1094-109 FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype. DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ (2014) Lab Invest 94: 726-39 Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium. Pruitt FL, He Y, Franco OE, Jiang M, Cates JM, Hayward SW (2013) Prostate 73: 476-88 Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, Strand DW (2014) Prostate 74: 669-79 Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW (2005) Prostate 64: 149-59 NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW (2016) Prostate 76: 1004-18 NF-κB and androgen receptor variant expression correlate with human BPH progression. Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW (2016) Prostate 76: 491-511 Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Sherwood ER, Theyer G, Steiner G, Berg LA, Kozlowski JM, Lee C (1991) Prostate 18: 303-14 Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer. Love HD, Booton SE, Boone BE, Breyer JP, Koyama T, Revelo MP, Shappell SB, Smith JR, Hayward SW (2009) PLoS One 4: e8384 Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice. Martinez EE, Anderson PD, Logan M, Abdulkadir SA (2012) PLoS One 7: e46792 Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume. Giri A, Edwards TL, Motley SS, Byerly SH, Fowke JH (2015) PLoS One 10: e0132028 The effects of interferons on the activity of alpha-glycerolphosphate dehydrogenase in benign prostatic hyperplasia cells in primary culture. Hayward S, Cox S, Mitchell I, Hallowes R, Deshpande N, Towler J (1987) J Urol 138: 648-53 A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. Cannon GW, Mullins C, Lucia MS, Hayward SW, Lin V, Liu BC, Slawin K, Rubin MA, Getzenberg RH (2007) J Urol 177: 610-4; discussion 614 Race and socioeconomic status are independently associated with benign prostatic hyperplasia. Fowke JH, Murff HJ, Signorello LB, Lund L, Blot WJ (2008) J Urol 180: 2091-6; discussion 2096 Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. Nichol MB, Knight TK, Wu J, Barron R, Penson DF (2009) J Urol 181: 2214-21; discussion 2221-2 Update on AUA guideline on the management of benign prostatic hyperplasia. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT (2011) J Urol 185: 1793-803 Divergent effects of interferons on the growth of human benign prostatic hyperplasia cells in primary culture. Deshpande N, Hallowes RC, Cox S, Mitchell I, Hayward S, Towler JM (1989) J Urol 141: 157-60 A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium. Mullins C, Lucia MS, Hayward SW, Lee JY, Levitt JM, Lin VK, Liu BC, Chinnaiyan AM, Rubin MA, Slawin K, Star RA, Getzenberg RH, MPSA Consortium (2008) J Urol 179: 1243-56 Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C (1990) J Urol 143: 167-71 A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments. Pacheco JA, Rasmussen LV, Kiefer RC, Campion TR, Speltz P, Carroll RJ, Stallings SC, Mo H, Ahuja M, Jiang G, LaRose ER, Peissig PL, Shang N, Benoit B, Gainer VS, Borthwick K, Jackson KL, Sharma A, Wu AY, Kho AN, Roden DM, Pathak J, Denny JC, Thompson WK (2018) J Am Med Inform Assoc 25: 1540-1546 Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. Fowke JH, Munro H, Signorello LB, Blot WJ, Penson DF, Urologic Diseases of America Project (2011) J Gen Intern Med 26: 1305-10 The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Fowke JH, Motley SS, Barocas DA, Cookson MS, Concepcion R, Byerly S, Smith JA (2011) Cancer Causes Control 22: 417-26 Two-dimensional protein profiles of cultured stromal and epithelial cells from hyperplastic human prostate. Sherwood ER, Berg LA, McEwan RN, Pasciak RM, Kozlowski JM, Lee C (1989) J Cell Biochem 40: 201-14 Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. Fowke JH, Phillips S, Koyama T, Byerly S, Concepcion R, Motley SS, Clark PE (2013) BJU Int 111: 122-8 Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network. Hellwege JN, Stallings S, Torstenson ES, Carroll R, Borthwick KM, Brilliant MH, Crosslin D, Gordon A, Hripcsak G, Jarvik GP, Linneman JG, Devi P, Peissig PL, Sleiman PAM, Hakonarson H, Ritchie MD, Verma SS, Shang N, Denny JC, Roden DM, Velez Edwards DR, Edwards TL (2019) Sci Rep 9: 6077 MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: A Comparison With AMACR. Goldstein J, Goyal R, Roland JT, Gellert LL, Clark PE, Hameed O, Giannico GA (2016) Am J Clin Pathol 146: 294-302 PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW (2011) Differentiation 82: 220-36 MAGI-2 in prostate cancer: an immunohistochemical study. Goldstein J, Borowsky AD, Goyal R, Roland JT, Arnold SA, Gellert LL, Clark PE, Hameed O, Giannico GA (2016) Hum Pathol 52: 83-91 The association between body size, prostate volume and prostate-specific antigen. Fowke JH, Motley SS, Cookson MS, Concepcion R, Chang SS, Wills ML, Smith JA (2007) Prostate Cancer Prostatic Dis 10: 137-42 SOX2 expression in the developing, adult, as well as, diseased prostate. Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ (2014) Prostate Cancer Prostatic Dis 17: 301-9 Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. Neuhouser ML, Kristal AR, Penson DF (2004) Urology 64: 201-11
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.